Hello, and welcome to the Paysign Fourth Quarter 2021 Earnings Conference Call. As a reminder, this conference is being recorded. This presentation may include forward-looking statements to the extent that the information is presented in this presentation discusses financial projections, information, or expectations about the company's business plans, results of operations, the impact of COVID-19, returns on equity, expected gross margins, markets, or otherwise make statements about future events. Such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as should, may, intends, anticipates, believes, estimates, projects, forecasts, expects, plans, and proposals. Although the Company believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading Risk Factors and elsewhere in Form 10-K. Forward-looking statements speak only as of the date of the document in which they are contained, and the Company does not undertake any duty to update any forward-looking statements except as may be required by law. This presentation also includes adjusted EBITDA, a non-GAAP financial measure that is neither prepared in accordance with GAAP nor an alternative to financial measures prepared in accordance with GAAP and is not necessarily comparable to similarly titled measures presented by other companies. It is now my pleasure to turn the call over to Mark Newcomer. Please go ahead. Good afternoon, everyone, and thank you for joining us for Paysign's fourth quarter and full year 2021 earnings call. I'm Mark Newcomer, Chief Executive Officer, and with me this afternoon is Jeff Baker, our Chief Financial Officer. Everyone touch wood because I don't want to jinx this, but I'm very happy to say that it looks as though we are starting to see the effects of the pandemic on our business subside. Throughout the fourth quarter, we saw our load and spending trends continue to improve as the number of plasma donations increased, as well as seeing an increase in average donation compensation. Funds loaded on cards was up 12.5% over fourth quarter last year and up 4.6% over last quarter. On a full year basis, funds loaded was up 10% over 2020. The fourth quarter spend volume increased 13.2% from last year and was up 5.4% over last quarter. For the full year, spend volume was up 14.3% over the previous year. As a result of these positive trends, our Q4 revenues of $8.8 million increased 21% versus the prior year. For the full year, our revenues increased 22% to $29.5 million over the previous year. In addition to the positive transaction trends, we also saw our plasma clients resume their expansion plans. In 2021, we signed six new plasma clients and onboarded an additional 26 net new plasma centers. In the fourth quarter, we added seven new plasma centers, ending the year with a total of 366 centers. With the increase in new centers and the increase in transaction volumes, we saw a 20% increase in plasma revenues and an increase in monthly revenue per center to $6,800 per center. In Q4, we renewed one of our large plasma clients. In addition to the contract renewal, we expect to be awarded additional centers from this client in 2022. Barring any unforeseen new COVID restrictions or change in our plasma clients' plans, we are expecting the number of new center onboarding in 2022 to surpass 2021's totals, as indicated by all of our clients' short-term and long-term growth plans, as well as new entrants in the plasma space. Throughout the year, we introduced a variety of cardholder benefits across our Plasma and Paysign Premier portfolios, including Paysign Pays, our merchant cashback rewards program, and the Paysign Pharmacy Discount Program. We continued to see new client acquisition and program launches in our Patient Affordability business. Two programs launched on schedule during the month of November. One of these programs is a hybrid program with both pharmacy and medical benefit, something we have discussed in our previous earnings call. We are pleased to see these programs building volume since launch. In December, we launched an additional retail pharmacy-based program for a pharmaceutical manufacturer client. This program is projected to be our largest volume Patient Affordability program at the time of launch. As we close out the fourth quarter, we continue to build on our excellent relationship with our hub and pharmaceutical manufacturer partners. We signed a new statement of work for a program that launched in the first quarter of 2022. This new program, supporting a new-to-market eye drop that has the potential to be a high volume program and is first of its kind used to support a retail pharmacy product launch. We spent much of our time focusing on leads and interest generated at Asembia 2021 and the outstanding level of interest in our unique selection of products and services. We have had numerous positive follow-ups since that October meeting and are on track to have an excellent year of new client acquisition and program launches in 2022. I'm excited about what lies ahead of us in 2022 and beyond. We continue to execute on our strategy to grow and protect our core plasma business, diversifying the new markets and verticals with new products like payroll, general purpose reloadable, corporate rewards and incentives, and our digital bank account. Build new business lines at the intersection of fintech and healthcare through our patient affordability business and to deliver operational excellence by continuing to build a world-class team and platform. We have a strong pipeline for 2022 across plasma, patient affordability, as well as the other prepaid product lines. Finally, 2021 was a challenging year for our cardholders, our clients, and for us as the pandemic and related stimulus packages impacted cardholder donations and spending behaviors and our clients delayed or slowed their growth plans. As I mentioned at the start of my comments, it looks as though we have turned the corner and are back on the path to growth. I am extremely proud of the Paysign team who stuck with it and continued to work hard through these challenges and enable us to deliver our improving quarterly and full-year results. With that, I'll pass it over to Jeff to give you more insight on our financials for the quarter and the full year 2021. Thank you, Mark. Good afternoon, everyone. As Mark pointed out, we had another good quarter with revenues, income from operations, EBITDA, adjusted EBITDA, and transactional trends all improving both sequentially and year-over-year. We met or exceeded all guidance metrics provided during our Q1 earnings call last May. Full year total revenue of $29.5 million was in line with our guidance of $29 million-$32 million. Gross profit margin was 49.9%, well ahead of our guidance of 45%. Operating expenses were $17.5 million, slightly below our initial guidance of $18 million-$18.5 million. Adjusted EBITDA of $2 million was ahead of our guidance of $350,000-$1.9 million. With all the details we provided in the press release and that will be available in our 10-K when it's published tomorrow, I will simply hit the financial highlights for the fourth quarter relative to the fourth quarter of 2020. Total revenues of $8.8 million increased $1.5 million over the previous year. Of that amount, plasma revenues were $7.6 million, up 19.9%, and pharma revenues were up 27.8% to $1.2 million. Other revenue was up slightly to $37,000. The average revenue per month per plasma center was $6,798 versus $6,660 last year, and we exited the year with 366 centers versus 340 at the end of last year. Gross profit margin for the quarter was 54.3% versus 51.2%, an increase of over 300 basis points. SG&A was up 5.4% to $4 million, and total operating expenses were up 6.5% to $4.7 million as we continue to invest in our operations and technology platform. Adjusted EBITDA, which adds back stock compensation to EBITDA, was $1.3 million or $0.02 per diluted share. This was up 64.5% over last year's adjusted EBITDA of $768,000. Regarding the health of our company, we exited the quarter with $7.4 million in unrestricted cash and zero debt, which is an increase of $460,000 from our third quarter ending cash balance. If I can sum up all of the year-over-year improvements into two words, that would be operating leverage, meaning as our top line grows, we should continue to see a greater incremental growth in our operating results despite the need to continue to invest in our people and technology platform. Looking at 2022, as Mark said, we are excited about what lies ahead of us as we expect our core plasma business to continue to improve over 2021 results and our pharma co-pay business to continue on the positive momentum it experienced in 2021. Looking at all of the factors driving our business from a revenue and cost perspective, we would like to provide some guidance of where we see 2022 going from a financial perspective. First, total revenues are expected to be in the range of $35.25 million-$38.35 million, reflecting growth of 20%-30%, with plasma making up approximately 90% of total revenue. Pharma revenue is expected to be relatively flat year-over-year as the loss of programs and settlement income that was recorded in 2021 are offset with new pharma co-pay programs. Second, adjusted EBITDA is expected to at least double to $4 million over 2021's adjusted EBITDA of $2 million. Third, full year gross profit margins are expected to be approximately 50%-52.5%, with Q1 2022 gross profit margin expected to be approximately 60% before returning to a more normalized gross profit margin experienced in 2021. We believe this will result in Q1 2022 operating results to be somewhat skewed relative to historical Q1 results. Fourth, operating expenses are expected to increase to approximately $20 million as we continue to make investments in people and technology and experience higher costs in insurance, travel and entertainment, and other inflationary pressures. Lastly, depreciation and amortization is expected to be between $3 million and $3.25 million, while stock-based compensation is expected to be approximately $2 million. With that, I would like to turn the call back over to the moderator for question and answers. Thank you. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. Our first question is from Peter Heckmann with D.A. Davidson. Please proceed. Hey, good afternoon, everyone. Thanks for taking the question. I believe I heard you say that you expect the net new plasma centers, the net new additions in 2022 to be greater than 2021. If you could verify that, but then as well, I think going back a couple quarters, you had talked about a pipeline of about 60 centers. Can you talk a little bit about that pipeline and you know, maybe what the conservative number might be, but if a couple of things break the right way, what type of number we might be looking for over the next four to six quarters? Yeah. Hey, Pete, it's Mark, and I'm happy to discuss that with you. You know, basically, let me address first your question about the 50 that was in prior quarters. You know, we do absolutely believe that we will beat the numbers that we did last year with net new centers. We're expecting that number to be close to 40, and that can go ±. That's helpful. Just in terms of thinking about that gross margin in the first quarter, is there any unusual item in there, or it's just, you know, that you won't be able to ramp some of your planned investments in people and technology as fast as the revenue's coming back? Hey, Pete, this is Jeff. If you heard Mark say we renewed a large plasma customer during the quarter, part of that renewal and negotiation and some things is gonna cause us to have a one-time benefit on the cost of sales line for the first quarter. What you're gonna see is, per the guidance, roughly like a 60% gross margin, and then it's gonna go back to the upper 40s kinda throughout the rest of the year. The second quarter, third quarter, fourth quarter. What that's also gonna result in is you're gonna see kinda like a smiley face as you get to adjusted EBITDA, where you're gonna have a high number in the first quarter, then it'll go down in the second. You know, remember, second to third quarter is kinda flattish, maybe up a little bit in the third quarter, and then it'll go up in the fourth quarter. Again, that's tracking with the seasonality that you see in our business. You know, keep in mind, January looks good, and February falls off with tax season. March starts to rebound, and the plasma revenue ramps up throughout the remainder of the year. I'm just trying to give as much visibility out there for everyone so they understand kinda the plus and takes that are going on in the model this year. That's helpful. Maybe just one more, and then I'll get back in the queue. On the pharma side, I think you noted maybe two net new for the year. Just trying to figure out where we are then. You know, are we at about, I don't know, mid-teens type in terms of number of programs? I mean, I know it's not. The programs can, you know, vary more significantly than the plasma centers. Just in terms of, like, the total pharma programs you might be working on as you enter 2022. Is it? Are we thinking about that right, about, you know, 15, 16, 17 type programs? Well, on the Q2 net revenue, we had some programs that ended, and then that's what happens. You know, these are two-three-year contracts, and sometimes they renew, and sometimes they just end. In the quarter, we had a couple ended, and those are on the kind of the old, I'm gonna say the old model versus the new model, the new co-pay business model that we're having a lot of traction in and then the legacy prepaid model. Today, I think I mean, I'd be guessing, but we're probably in the 10-15 range of the number of programs. We're 17. Sorry. 17 programs. I don't have to guess. Mark told me. We're at 17 programs, and then we'll continue to add more of those throughout 2022. What's hard to see from an outsider's perspective is you have the old legacy prepaid business kinda declining from left to right. We've got a couple of programs left there that will end in 2022. You got the growth of the new co-pay business from the bottom left going up to the right for 2022. That's why you're looking at kinda like a flattish revenue in the pharma business what really starts around, you know, call it $700,000, around that in the first quarter, you know, going to $750-ish, and then exiting around $850 for the year. That should get you pretty close to flattish year-over-year. Got it. Okay, great. Thank you. I'll get back in the queue. Yep. As a reminder, just star one on your telephone keypad if you would like to ask a question. We will just pause for a brief moment to poll for questions. There are no further questions at this time. I would like to turn the conference back over to management for closing comments. Thanks, Sherry. Really appreciate everyone's time and interest today. Wanna also thank the Paysign team for their continued dedication and hard work. With that, thank you very much. Have a great day. Thank you. This does conclude today's conference. You may disconnect your lines at this time, and thank you for your participation.